Pharmaceutical

Layoffs, Rivals, and the Future of Ocular Therapeutix Ocular Therapeutix Ocular Therapeutix is advancing retinal disease treatments with its ELUTYX hydrogel platform, featuring long-acting implants like AXPAXLI™ for wet AMD and DEXTENZA® for post-surgical inflammation and allergic conjunctivitis.
Innovative Drugs: The Changing Times FDA ADC Recent advancements in ADC therapies are reshaping cancer treatment. AstraZeneca and Gilead's breakthroughs in first-line therapies for breast and TNBC cancers mark a new era in innovative drug development.
Biotech Drives Innovation, Big Pharma Creates Blockbusters Market Trend Explore how Biotech drives innovation and Big Pharma delivers blockbusters in the FIC drug landscape. Discover key insights on collaboration, commercialization, and the future of China's pharmaceutical industry.
BMS Schizophrenia Adjunct Therapy Cobenfy Phase III Trial Results Fail BMS Bristol Myers Squibb's Phase III ARISE trial of Cobenfy as adjunctive therapy for schizophrenia did not meet its primary endpoint but showed encouraging trends and a consistent safety profile.
NIH Cuts and the Future of U.S. Biopharma NIH Biopharmaceutical Trump's proposed NIH budget cuts, agency consolidations, and funding restrictions could reshape U.S. biomedical research, strain U.S.-China collaborations, and shift national priorities toward AI and space tech.
Sanofi: Potential Super Heavy Bomb Stumbles Sanofi Sanofi's Amlitelimab, an OX40L monoclonal antibody, stumbles in asthma trials. With a strong potential in atopic dermatitis, this drug faces competition from Dupixent. OX40's future in autoimmune diseases remains promising despite challenges.
$345 Million Deal: Boehringer Ingelheim and Cue Biopharma Launch New Era in Autoimmune Disease Treatment Boehringer Ingelheim Boehringer Ingelheim partners with Cue Biopharma in a $345M deal to develop CUE-501, a next-gen bispecific antibody therapy targeting autoimmune diseases with precision and improved safety.
Top 10 Oncology Products by Global Sales in 2024 Oncology Market Trend Merck Roche AstraZeneca Explore the top 10 global oncology drugs of 2024 by sales. Discover leading therapies like Keytruda and Darzalex, modality trends, solid vs. blood tumor market insights, and the growing role of cell and gene therapies.
Global Biopharma Layoffs April 2025 Layoffs Pfizer Gilead Stay updated on recent global biopharma layoffs in April 2025. Learn about job cuts, restructuring plans, and the latest industry developments across leading biotech and pharma companies.
Johnson & Johnson's Q1 2025 Financial report Johnson & Johnson Market Trend Financial statements Johnson & Johnson's Q1 2025 report shows a 135% sales surge for CARVYKTI, a CAR-T therapy co-developed with Legend Biotech, with projected annual sales hitting $2B. Oncology drug sales also saw strong growth.

< Pre 1...54 55 565758 59 60...87 Next >

Articles Archives

Hot Articles

Related Exhibition

All Categories

Agri & Industry Cosmetic Food History Laboratory

HOT Topics

Hot Articles